277 related articles for article (PubMed ID: 34406395)
1. Effect of Sitagliptin on Islet Function in Pancreatic Insufficient Cystic Fibrosis With Abnormal Glucose Tolerance.
Kelly A; Sheikh S; Stefanovski D; Peleckis AJ; Nyirjesy SC; Eiel JN; Sidhaye A; Localio R; Gallop R; De Leon DD; Hadjiliadis D; Rubenstein RC; Rickels MR
J Clin Endocrinol Metab; 2021 Aug; 106(9):2617-2634. PubMed ID: 34406395
[TBL] [Abstract][Full Text] [Related]
2. Effects of GLP-1 and GIP on Islet Function in Glucose-Intolerant, Pancreatic-Insufficient Cystic Fibrosis.
Nyirjesy SC; Peleckis AJ; Eiel JN; Gallagher K; Doliba A; Tami A; Flatt AJ; De Leon DD; Hadjiliadis D; Sheikh S; Stefanovski D; Gallop R; D'Alessio DA; Rubenstein RC; Kelly A; Rickels MR
Diabetes; 2022 Oct; 71(10):2153-2165. PubMed ID: 35796669
[TBL] [Abstract][Full Text] [Related]
3. Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus.
Aaboe K; Knop FK; Vilsbøll T; Deacon CF; Holst JJ; Madsbad S; Krarup T
Diabetes Obes Metab; 2010 Apr; 12(4):323-33. PubMed ID: 20380653
[TBL] [Abstract][Full Text] [Related]
4. Dysregulated insulin in pancreatic insufficient cystic fibrosis with post-prandial hypoglycemia.
Kilberg MJ; Sheikh S; Stefanovski D; Kubrak C; De Leon DD; Hadjiliadis D; Rubenstein RC; Rickels MR; Kelly A
J Cyst Fibros; 2020 Mar; 19(2):310-315. PubMed ID: 31402215
[TBL] [Abstract][Full Text] [Related]
5. β-Cell secretory defects are present in pancreatic insufficient cystic fibrosis with 1-hour oral glucose tolerance test glucose ≥155 mg/dL.
Nyirjesy SC; Sheikh S; Hadjiliadis D; De Leon DD; Peleckis AJ; Eiel JN; Kubrak C; Stefanovski D; Rubenstein RC; Rickels MR; Kelly A
Pediatr Diabetes; 2018 Nov; 19(7):1173-1182. PubMed ID: 29885044
[TBL] [Abstract][Full Text] [Related]
6. Very short-term effects of the dipeptidyl peptidase-4 inhibitor sitagliptin on the secretion of insulin, glucagon, and incretin hormones in Japanese patients with type 2 diabetes mellitus: analysis of meal tolerance test data.
Murai K; Katsuno T; Miyagawa J; Matsuo T; Ochi F; Tokuda M; Kusunoki Y; Miuchi M; Namba M
Drugs R D; 2014 Dec; 14(4):301-8. PubMed ID: 25420579
[TBL] [Abstract][Full Text] [Related]
7. Reduced β-Cell Secretory Capacity in Pancreatic-Insufficient, but Not Pancreatic-Sufficient, Cystic Fibrosis Despite Normal Glucose Tolerance.
Sheikh S; Gudipaty L; De Leon DD; Hadjiliadis D; Kubrak C; Rosenfeld NK; Nyirjesy SC; Peleckis AJ; Malik S; Stefanovski D; Cuchel M; Rubenstein RC; Kelly A; Rickels MR
Diabetes; 2017 Jan; 66(1):134-144. PubMed ID: 27495225
[TBL] [Abstract][Full Text] [Related]
8. Endogenous Glucose-Dependent Insulinotropic Polypeptide Contributes to Sitagliptin-Mediated Improvement in β-Cell Function in Patients With Type 2 Diabetes.
Stensen S; Gasbjerg LS; Rosenkilde MM; Vilsbøll T; Holst JJ; Hartmann B; Christensen MB; Knop FK
Diabetes; 2022 Oct; 71(10):2209-2221. PubMed ID: 35796651
[TBL] [Abstract][Full Text] [Related]
9. Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes.
Nauck MA; Kahle M; Baranov O; Deacon CF; Holst JJ
Diabetes Obes Metab; 2017 Feb; 19(2):200-207. PubMed ID: 27709794
[TBL] [Abstract][Full Text] [Related]
10. Feedback suppression of meal-induced glucagon-like peptide-1 (GLP-1) secretion mediated through elevations in intact GLP-1 caused by dipeptidyl peptidase-4 inhibition: a randomized, prospective comparison of sitagliptin and vildagliptin treatment.
Baranov O; Kahle M; Deacon CF; Holst JJ; Nauck MA
Diabetes Obes Metab; 2016 Nov; 18(11):1100-1109. PubMed ID: 27300579
[TBL] [Abstract][Full Text] [Related]
11. Restoration of the insulinotropic effect of glucose-dependent insulinotropic polypeptide contributes to the antidiabetic effect of dipeptidyl peptidase-4 inhibitors.
Aaboe K; Akram S; Deacon CF; Holst JJ; Madsbad S; Krarup T
Diabetes Obes Metab; 2015 Jan; 17(1):74-81. PubMed ID: 25243647
[TBL] [Abstract][Full Text] [Related]
12. Does dipeptidyl peptidase-4 inhibition prevent the diabetogenic effects of glucocorticoids in men with the metabolic syndrome? A randomized controlled trial.
van Genugten RE; van Raalte DH; Muskiet MH; Heymans MW; Pouwels PJ; Ouwens DM; Mari A; Diamant M
Eur J Endocrinol; 2014 Mar; 170(3):429-39. PubMed ID: 24297090
[TBL] [Abstract][Full Text] [Related]
13. Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice.
Waget A; Cabou C; Masseboeuf M; Cattan P; Armanet M; Karaca M; Castel J; Garret C; Payros G; Maida A; Sulpice T; Holst JJ; Drucker DJ; Magnan C; Burcelin R
Endocrinology; 2011 Aug; 152(8):3018-29. PubMed ID: 21673098
[TBL] [Abstract][Full Text] [Related]
14. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.
Herman GA; Bergman A; Stevens C; Kotey P; Yi B; Zhao P; Dietrich B; Golor G; Schrodter A; Keymeulen B; Lasseter KC; Kipnes MS; Snyder K; Hilliard D; Tanen M; Cilissen C; De Smet M; de Lepeleire I; Van Dyck K; Wang AQ; Zeng W; Davies MJ; Tanaka W; Holst JJ; Deacon CF; Gottesdiener KM; Wagner JA
J Clin Endocrinol Metab; 2006 Nov; 91(11):4612-9. PubMed ID: 16912128
[TBL] [Abstract][Full Text] [Related]
15. Addition of sitagliptin or metformin to insulin monotherapy improves blood glucose control via different effects on insulin and glucagon secretion in hyperglycemic Japanese patients with type 2 diabetes.
Otsuka Y; Yamaguchi S; Furukawa A; Kosuda M; Nakazaki M; Ishihara H
Endocr J; 2015; 62(2):133-43. PubMed ID: 25328079
[TBL] [Abstract][Full Text] [Related]
16. Effects of endogenous GLP-1 and GIP on glucose tolerance after Roux-en-Y gastric bypass surgery.
Svane MS; Bojsen-Møller KN; Nielsen S; Jørgensen NB; Dirksen C; Bendtsen F; Kristiansen VB; Hartmann B; Holst JJ; Madsbad S
Am J Physiol Endocrinol Metab; 2016 Apr; 310(7):E505-14. PubMed ID: 26786780
[TBL] [Abstract][Full Text] [Related]
17. Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial.
Garg SK; Moser EG; Bode BW; Klaff LJ; Hiatt WR; Beatson C; Snell-Bergeon JK
Endocr Pract; 2013; 19(1):19-28. PubMed ID: 23186950
[TBL] [Abstract][Full Text] [Related]
18. Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance.
Rosenstock J; Foley JE; Rendell M; Landin-Olsson M; Holst JJ; Deacon CF; Rochotte E; Baron MA
Diabetes Care; 2008 Jan; 31(1):30-5. PubMed ID: 17947341
[TBL] [Abstract][Full Text] [Related]
19. The effect of DPP-4 inhibition with sitagliptin on incretin secretion and on fasting and postprandial glucose turnover in subjects with impaired fasting glucose.
Bock G; Dalla Man C; Micheletto F; Basu R; Giesler PD; Laugen J; Deacon CF; Holst JJ; Toffolo G; Cobelli C; Rizza RA; Vella A
Clin Endocrinol (Oxf); 2010 Aug; 73(2):189-96. PubMed ID: 20039889
[TBL] [Abstract][Full Text] [Related]
20. Early-phase insulin secretion during mixed-meal tolerance testing predicts β-cell function and secretory capacity in cystic fibrosis.
Sheikh S; Stefanovski D; Kilberg MJ; Hadjiliadis D; Rubenstein RC; Rickels MR; Kelly A
Front Endocrinol (Lausanne); 2024; 15():1340346. PubMed ID: 38444582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
